Compare Abbott Laboratories (ABT) vs Synchrony Financial (SYF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Synchrony Financial — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Synchrony Financial trades at $71.98 (market cap $25.40B). The key difference: Abbott Laboratories is far larger — about 6.6× Synchrony Financial's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | SYF | |
|---|---|---|
Market Cap | $166.94B | $25.40B |
Sector | Health | Financials |
52-Week High | $136.62 | $88.47 |
52-Week Low | $82.57 | $63.78 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
SYF trades at $77.05, up 0.94% today, with a bullish technical outlook supported by moving averages and key resistance at $78. The stock shows strong fundamentals with a P/E of 7.98, net income margin of 24.06%, and consistent earnings beats in recent quarters. Recent news highlights executive changes and partnership expansions, reinforcing growth initiatives.
The outlook remains positive with a consensus price target of $85, representing ~10% upside. Risks include interest rate sensitivity and competitive pressures, but strong analyst buy ratings (62.5%) and robust cash flow support a favorable investment case for value-oriented investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
